Entecavir is generally used for the treatment of chronic viral hepatitis B. It has no direct therapeutic effect on post-hepatitis cirrhosis. Entecavir is used for the treatment of chronic viral hepatitis B. When patients check hepatitis B DNA suggesting that the virus has replication, check liver function suggesting elevated glutamic and glutamic aminotransferases, or liver hardness test with obvious manifestations of liver fibrosis, patients can consider oral entecavir for antiviral therapy at this time. After entecavir is taken, patients need to take the drug for a long time to avoid intermediate discontinuation, and there is a risk of rebound viral replication activity after discontinuation of the drug. Entecavir is more effective in treating viral replication in patients, but generally has no direct therapeutic effect on the treatment of post-hepatitis cirrhosis. Its main therapeutic effect is still to resist the replication of the patient’s virus and treat the patient’s viral infection. As long as the patient’s viral infection replication is improved, the condition of hepatitis B cirrhosis will also be stable and improved. Therefore, for liver fibrosis caused by post-hepatitis cirrhosis, we should actively consider antiviral therapy, which can be combined with the application of anti-liver fibrosis drugs. The main drugs for antiviral treatment are entecavir, lamivudine and other drugs. Anti-hepatic fibrosis drugs such as ligandron and hydralinga are also available.